請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/37367
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 翁啟惠(Chi-Huey Wong) | |
dc.contributor.author | Yen-Lin Huang | en |
dc.contributor.author | 黃彥霖 | zh_TW |
dc.date.accessioned | 2021-06-13T15:25:44Z | - |
dc.date.available | 2010-07-21 | |
dc.date.copyright | 2008-07-21 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-07-18 | |
dc.identifier.citation | 1. Meezan, E., Wu, H. C., Black, P. H., and Robbins, P. W. Comparative studies on carbohydrate containing membrane components of normal and virus transformed mouse fibroblasts. Biochemistry 1969, 8, 2518-2524.
2. Turner, G. A. N-glycosylation of serum proteins in disease and its investigation using lectins. Clin. Chirn. Acta. 1992, 208, 149-171. 3. Gabius, H. J. Biological information transfer beyond the genetic code: the sugar code. Naturwissenschaften. 2000, 87, 108-121. 4. Shriver, Z., Raguram, S., and Sasisekharan, R. Glycomics: a pathway to a class of new and improved therapeutics. Nat. Rev. Drug. Disc. 2004, 3, 863-873. 5. Pacino, G. Osinaga, E., Charpin, C., Mistro, D., Barque, J. P., and Roseto, A. Purification and characterization of a breast cancer associated glycoprotein not expressed in normal breast and identified by monoclonal antibody. Br. J. Cancer. 1991, 63, 390-398. 6. Bremer, E.G., Levery, S.B., Sonnino, S., Ghidoni, R., Canevari, S., Kannagi, R., and Hakomori, S. Characterization of a glycosphingolipid antigen defined by the monoclonal antibody MBr1 expressed in normal and neoplastic epithelial cells of human mammary gland. J. Biol. Chem. 1984, 259, 14773–14777. 7. Ragupathi G., and Livingston, P. O. Cancer vaccines targeting carbohydrate antigens. Hum vaccin. 2006, 2, 137-143. 8. Zhang, S., Cordon-Cardo, C., Zhang, H. S., Reuter, V. E., Adluri, S., Hamilton, W. B., Lloyd, K. O., and Livingston, P. O. Selection of tumor antigens as targets to immune attack using immunohistochemistry (gangliosides). Int. J. Cancer. 1997, 73, 42-49. 9. Zhang, S., Zhang, H. S., Cordon-Cardo, C., Reuter, V. E., Adluri, S., Hamilton, W. B., Lloyd, K. O., and Livingston, P. O. Selection of tumor antigens as targets to immune attack using immunohistochemistry (blood group related antigens). Int. J. Cancer. 1997, 73, 50-56. 10. Bertozzi, C. R., and Dube, D. H. Glycans in cancer and inflammation: potential for therapeutics and diagnostics. Nat. Rev. Drug. Discov. 2005, 4, 477-488. 11. Bilodeau, M. T., Park, T. K., Hu, S., Randolph, J. T., Danishefsky, S. J., Livingston, P. O., and Zhang, S. Total synthesis of a human breast tumor associated antigen. J. Am. Chem. Soc. 1995, 117, 7840-7841. 12. Park, T. K., Kim, I. J., Hu, S., Bilodeau, M. T., Randolph, J. T., Kwon, O., and Danishefsky, S. J. Total synthesis and proof of structure of a human breast tumor (Globo H) antigen. J. Am. Chem. Soc. 1996, 118, 11488-11500. 13. Lassaletta, J. M., and Schmidt, R. R. Synthesis of complex glycosphingolipids of the globo series. Liebigs. Ann. 1996, 1417-1423. 14. Zhu, T., and Boons, G. J. A two directional and highly convergent approach for the synthesis of the tumor associated antigen Globo H. Angew. Chem. Int. Ed. 1999, 38, 3495-3497. 15. Bosse, F., Marcaurelle, L. A., and Seeberger, P. H. Linear synthesis of the tumor associated carbohydrate antigens Globo H, SSEA-3, and Gb3. J. Org. Chem. 2002, 67, 6659-6670. 16. Werz, D. B., Castagner, B., and Seeberger, P. H. Automated synthesis of the tumor associated carbohydrate antigens Gb-3 and Globo H. J. Am. Chem. Soc. 2007, 129, 2770-2771. 17. Burkhart, F., Zhang, Z. Y., Wacowich-Sgarbi, S., and Wong, C. H. Synthesis of the Globo H hexasaccharide using the programmable reactivity-based one-pot strategy. Angew. Chem. Int. Ed. 2001, 40, 1274-1277. 18. Huang, C.Y., Thayer, D. A., Chang, A.Y., Best, M.D., Hoffmann, J., Head, S., and Wong, C. H. Carbohydrate microarray for profiling the antibodies interacting with Globo H tumor antigen. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 15-20. 19. Su, D. M., Eguchi, H., Yi, W., Li, L., Wang, P. G., and Xia, C. F. Enzymatic synthesis of tumor associated carbohydrate antigen Globo H hexasaccharide. Org. lett. 2008, 10, 1009-1012. (b) Zhao, H., and van der Donk, W. A. Regeneration of cofactors for use in biocatalysis. Curr. Opin. Biotechnol. 2003, 14, 583-589. 20. Jones, C. Vaccines based on the cell surface carbohydrates of pathogenic bacteria. An. Acad. Bras. Cienc. 2005, 77, 293-324. 21. Verez-bencomo, V., Fernandez-Santana, V., Hardy, E., Toledo, M. E., Rodriguez. M. C., Heynngnezz, L., Rodriguez, A., Baly, A., Herrera, L., Izquierdo, M., Villar, A., Valdes, Y., Cosme, K., Deler, M. L., Montane, M., Garcia, E., Ramos, A., Aguilar, A., Medina, E., Torano, G., Sosa, I., Hernandez, I., Martinez, R., Muzachio, A., Carmenates, A., Costa, L., Cardoso, F., Concepcion, C., Diaz, M., and Roy, R. A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science 2004, 305, 522-525. 22. Schofield, L., Hewitt, M. C., Evans, K., Siomos, M. A., and Seeberger, P. H. Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature 2002, 418, 785-789. 23. Kamena, F., Tamborrini, M., Liu, X., Kwon, Y. U., Thompson, F., Pluschke, G., and Seeberger, P. H. Synthetic GPI array to study antitoxic malaria response. Nat. Chem. Biol. 2008, 4, 238-240. 24. Wang, S. K., Liang, P. H., Astronomo, R. D., Hsu, T. L., Hsieh, S. L., Burton, D. R., and Wong, C. H. Targeting the carbohydrates on HIV-1: interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 3690-3695. 25. Ragupathi, G., Park, T. K., Zhang, S., Kin, I. J., Graber, L., Adluri, S., Lloyd, K. O., Danishefsky, S. J., and Livingston, P. O. Immunization of mice with a fully synthetic Globo H antigen results in antibodies against human cancer cells. Angew. Chem. Int. Ed. 1997, 36, 125-128. 26. Slovin, S. F., Ragupathi, G.., Adluri, S., Ungers, G., Terry, K., Kim, S., Spassova, M., Bornmann, W. G., Fazzari, M., Dantis, L., Olkiewicz, K., Lloyd, K. O., Livingston, P. O., Danishefsky, S. J., and Scher, H. I. Carbohydrate vaccines in cancer. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 5710-5715. 27. Gilewski, T., Ragupathi, G., Bhuta, S., Williams, L. J., Musselli, C., Zhang, X. F., Bencsath, K. P., Panageas, K. S., Chin, J., Hudis, C. A., Norton, L., Houghton, A. N., Livingston, P. O., and Danishefsky, S. J. Immunization of metastatic breast cancer patients with a fully synthetic Globo H conjugate: A phase I trial. Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 3270-3275. 28. Holmberg, L., and Sandmaier, B. Vaccination with theratope (STn-KLH) as treatment for breast cancer. Expert. Rev. Vaccines. 2004, 3, 655-663. 29. Meikle, P. J., and Bundle, D. R. Preparation of polysaccharide-enzyme competitive binding assays. Glycoconjugate J. 1990, 7, 207-218. 30. Wan, Q., Chen, J. H., and Danishefsky, S. J. A potentially valuable advance in the synthesis of carbohydrate-based anticancer vaccines through extended cycloaddition chemistry. J. Org. Chem. 2006, 71, 8244-8249. 31. Johansson, S. M., Arnberg, N., Elofsson, M., Wadell, G., and Kihlberg, J. Multivalent HSA conjugates of 3’-sialyllactose are potent inhibitors of adenoviral cell attachment and infection. J. ChemBioChem 2005, 6, 358-364. 32. Buskas, T., Li, Y., and Boons, G. J. The immunogenicity of the tumor-associated antigen Lewis(y) may be suppressed by a bifunctional cross-linker required for coupling to a carrier protein. Chem. Eur. J. 2004, 10, 3517-3524. 33. Wu, X., Ling, C. C., and Bundle, D. R. A new homobifunctionl p-nitro phenyl ester coupling reagent for the preparation of neoglycoproteins. Org. Lett. 2004, 6, 4407-4410. 34. Wu, X., and Bundle, D. R. Synthesis of glycoconjugate vaccines for Candida albicans using novel linker methodology. J. Org. Chem. 2005, 70, 7381-7388. 35. Sabbatini, P. J., Ragupathi, G., Hood, C., Aghajanian, C. A., Juretzka, M., Iasonos, A., Hensley, M. L., Spassova, M. K., Ouerfelli, O., Spriggs, D. R., Tew, W. P., Konner, J., Clausen, H., Rustum, N. A., Dansihefsky, S. J., and Livingston, P. O. Pilot study of a heptavalent vaccine keyhole limpet Hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube or peritoneal cancer. Clin. Cancer. Res. 2007, 13, 4170-4177. 36. Ingale, S., Wolfert, M. A., Gaekward, J., Buskas, T., and Boons, G. J. Robust immune responses elicited by a fully synthetic three-component vaccine. Nat. Chem. Biol. 2007, 3, 663-667. 37. Savage, P. B., Teyton, L., and Bendelac, A. Glycolipids for natural killer T cells Chem. Soc. Rev. 2006, 35, 771-779. 38. Wu, D., Xing, G. W., Poles, M. A., Horowitz, A., Kinjo, Y., Sullivan, B., Narkevitch, V. B., Plettenburg, O., Kronenberg, M., Tsuji, M., Ho, D. D., and Wong, C. H. Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells. Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 1351-1356. 39. Fujio, M., Wu, D., Garcia-Navaro, R., Ho, D. D., Tsuji, M., and Wong, C. H. Structure based discovery of glycolipids for CD1d mediated NKT cell activation. J. Am. Chem. Soc. 2006, 128, 9022-9023. 40. Chang, Y. J., Huang, J. R., Tsai, Y. C., Hung, J. T., Wu, D., Fujio, M., Wong, C. H., and Yu, A. L. Potent immune modulating and anticancer effects of NKT cell stimulatory glycolipids. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 10299-10304. 41. Wu, D., Fujio, M., and Wong, C. H. Glycolipids as immunostimulating agents. Bioorg. Med. Chem. 2007, 16, 1073-1083. 42. Paulson, J. C., Bilxt, O., and Collins, B. E. Sweet spots in functional glycomics. Nat. Chem. Biol. Rev. 2006, 2, 238-248. 43. Wang, D., Liu, S., Trummer, B. J., Deng, C., and Wang, A. Carbohydrate microarrays for the recognition of cross-reactive molecular markers of microbes and host cells. Nat. Biotechnol. 2002, 20, 275-281. 44. Ko, K. S., Jaipuri, F. A., and Pohl, N. L. Fluorous-based carbohydrate microarrays. J. Am. Chem. Soc. 2005, 127, 13162–13163. 45. Galanina, O. E., Mecklenburg, M., Nifantiev, N. E., Pazynina, G. V., and Bovin, N. V. GlycoChip: multiarray for the study of carbohydrate binding proteins. Lab Chip 2003, 3, 260–265. 46. Blixt, O., Head, S., Mondala, T., Scanlan, C., Huflejt, M. E., Alvarez, R., Bryan, M. C., Fazio, F., Calarese, D., Stevens, J., Razi, N., Stevens, D. J., Skehel, J. J., Die, I. V., Burton, D. R., Wilson, I. A., Cummings, R., Bovin, N., Wong, C. H., and Paulson, J. C. Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 17033–17038. 47. Bryan, M. C., Lee, L. V., and Wong, C. H. High-throughput identification of fucosyltransferase inhibitors using carbohydrate microarrays. Bioorg. Med. Chem. Lett. 2004, 14, 3185–3188. 48. Liang, P. H., Wu, C. Y., Greenberg, W. A., and Wong, C. H. Glycan arrays: biological and medical applications. Curr. Opin. Chem. Biol. 2008, 12, 86-92. 49. Stevens, J., Blixt, O., Tumpey, T. M., Taubenberger, J. K., Paulson, J. C., and Wilson, I. A. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science 2006, 312, 404-410. 50. Pouilly, P. D., Chenede, A., Mallet, J. M., and Sinay, P. Bull .Soc. Chim. Fr. 1993, 130, 256-265. 51. Zhang, Z., Ollmann, I. R., Ye, X. S., Wischnat, R., Bassov, T., and Wong, C. H. Programmable one-pot oligosaccharide synthesis J. Am. Chem. Soc. 1999, 121, 634-753. 52. Ariza, X., Urpi, F., Viladomat, C., and Vilarrasa, J. One-pot conversion of azides to Boc-protected amines with trimethylphosphine and Boc-ON. J. Tetrahedron Lett. 1998, 39, 9101-9102. 53. Nyffeler, P. T., Liang, C. H., Koeller, K. M., and Wong, C. H. The chemistry of amine-azide interconversion: catalytic diazotransfer and regioselective azide reduction. J. Am. Chem. Soc. 2002, 124, 10773-10778. 54. Wang, Z. G., Williams, L. J., Zhang, X. F., Zatorski, A., Kudryashov, V., Ragupathi, G., Spassova, M., Bornmann, W., Slovin, S. F., Scher, H. I., Livingston, P. O., and Danishefsky, S. J. Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 2719-2724. 55. Gupta, R. K., Collier, R. J., Rappuloi, R., and Siber, G. R. Differences in the immunogenicity of native and formalinized cross reacting material CRM197 of diphtheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs. Vaccine 1997, 15, 1341-1343. 56. Miyaji, E. N., Mazzantini, R. P., Dias, W. O., Nascimento L. T., Marcovistz, R., Matos, D., Raw, I., Winter, N., Gicquel, B., Rappuoli, R., and Leite, L. C. C. Induction of neutralizing antibodies against diphtheria toxin by priming with recombinant Mycobaterium bovis BCG expressing CRM197. Infect. Immun. 2001, 69, 869-874. 57. Godefroy, S., Peyre, P., Garcia, N., Muller, S., Sesardic, D., and Partidos, C. D. Effect of skin barrier disruption on immune responses to topically applied cross reacting material CRM197 of diphtheria toxin. Infect. Immun. 2005, 73, 4803-4809. 58. Stickings, P., Peyre, M., Coombes, L., Muller, S., Rappuoli, R., Giudice, G. D., Partidos, C. D., and Sesardic, D. Transcutaneous immunization with cross reacting material CRM197 of diphtheria toxin boosts functional antibody levels in mice primed parenterally with adsorbed diphtheria toxoid vaccine. Infect. Immun. 2008, 76, 1766-1773. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/37367 | - |
dc.description.abstract | 癌症的發生與轉移常伴隨著細胞表面異常的醣化現象。至今發現許多和腫瘤發展高度相關的醣抗原以醣蛋白或醣脂質的形式存在。其中由六個單醣所組成的Globo H (Fucα1→2Galβ1→3 GalNAcβ1→3Galα1→4Galβ1→4Glu)是由Hakamori 教授於1984年從乳癌細胞所分離出。而1995才由Danishefsky教授以glycal assembly方式首先合成出來。Globo H 大多表現在表皮類癌細胞上,而僅微量表現在正常組織中的分泌管道。所以科學家便根據Globo H表現的特異性設計疫苗及免疫療法來針對前列腺癌、乳癌、直腸癌、或卵巢癌。至今,雖然全世界還未有已核准的醣類抗癌疫苗,但在臨床實驗中已發現許多有潛力的疫苗能增加癌症患者的存活率。不過最終目標還是希望能徹底預防癌症術後的復發。因此,我們希望能依據前人的研究基礎來開發更有效的癌症疫苗。
在我們的研究中發現,若將此抗原接上蛋白及在佐劑的加成下可產生抗體。且對於異體移植癌細胞(4T1)的老鼠也觀察到有延遲腫瘤生長的效果。如果再藉由有系統的調整疫苗組成、佐劑種類、劑量、醣抗原比例、與時程,可望大幅提升免疫力來達到預防癌症的效果。最後,本研究團隊也正著手於相關醣抗原與新型載體的開發,以期望能發展出更有效的抗癌疫苗。 | zh_TW |
dc.description.abstract | Aberrant glycosylation is often a hallmark during tumor progression and correlates with poor prognosis. Diverse tumor associated antigens existed in the form of glycolipids or glycoproteins have been characterized. Globo H (Fucα1→2Galβ1→3 GalNAcβ1→3Galα1→4Galβ1→4Glu) hexasaccharide was first isolated from metastatic breast cancer cells by Hakomori in 1984 and initially synthesized by Danishefsky using glycal assembly strategy in 1995. Globo H was present on most cancers of epithelial origin, but only minimal expression on normal secretory tissue which is not readily accessible to immune system. Taking advantage of the exclusive expression signature, Globo H has been an attractive target for immunotherapy against prostate, breast, colon and ovarian cancers. Although, numerous vaccines are undergoing clinical evaluation and some shows improved survival rate in patients, the ultimate goal is to prevent the tumor recurrence. Therefore, we aim to develop a more effective vaccine and adjuvant against a variety of cancers.
Here we reported the promising carbohydrate based vaccine enhanced antibody production and delayed tumorigenesis in xenograft studies. Overall, systematic optimization with respect to formulation, adjuvant, dosage, glycan/protein ratio and timing of immunization regimen may further improve the protection against tumors. Finally, conjugation of diverse carbohydrate antigens to various carriers or dendrimer will be planned in the near further. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T15:25:44Z (GMT). No. of bitstreams: 1 ntu-97-R95b46011-1.pdf: 4433320 bytes, checksum: 6737cce5bab974e0e40b69150f4f890b (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | Table of Contents
Abstract …………………………… iv 中文摘要 …………………………… v Chapter 1 Introduction 1.1 Tumor associated carbohydrate antigens…………………………… 1 1.2 Chemical synthesis of Globo H hexasaccharide…………………… 3 1.3 Carbohydrate-based vaccines……………………………………..... 8 1.4 Applications of glycolipids as immunological adjuvants………….. 16 1.5 Applications and development of glycan microarray……………… 20 Chapter 2 Results and Discussion 2.1 Chemical synthesis of Globo H and derivatives…………………… 24 2.2 Generation of Globo H glycoconjugate and characterization……… 36 2.3 Glycan microarray fabrication and application…………………….. 39 2.4 Mouse immunized model…………………………………………... 43 2.5 References………………………………………………………….. 53 Chapter 3 Conclusion……………………………………………................... 61 Chapter 4 Materials and Methods…………………………......................... 63 Appendix Selected NMR and MASS spectra………………………….... 78 | |
dc.language.iso | en | |
dc.title | 發展抗乳癌疫苗與醣脂佐劑之應用 | zh_TW |
dc.title | Development of Globo H anti-breast cancer vaccines with novel glycolipid adjuvants | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 吳宗益(Chung-Yi Wu),陳鈴津(Alice Lin-Tsing Yu) | |
dc.contributor.oralexamcommittee | 林俊宏(Chun-Hung Lin) | |
dc.subject.keyword | 乳癌,疫苗,醣脂質,佐劑, | zh_TW |
dc.subject.keyword | breast cancer,vaccine,glycolipid,adjuvants, | en |
dc.relation.page | 98 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2008-07-18 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科學研究所 | zh_TW |
顯示於系所單位: | 生化科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-97-1.pdf 目前未授權公開取用 | 4.33 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。